How to Implement Good Laboratory Practices in Small-Scale Labs?

Regulatory compliance in pharmaceutical research and drug development is of utmost importance. Hence, the implementation of good laboratory practices has become critical for large and small-scale laboratories in the drug discovery and development sector. GLP bioanalysis is a comprehensive system designed to ensure regulatory compliance and data integrity in nonclinical studies. GLP bioanalysis is a specialized process requiring rigorous compliance with FDA regulations.

Bioanalytical laboratories, especially small-scale labs, face unique challenges in implementing GLP systems while maintaining cost-effectiveness and operational efficiency. This article explores systematic GLP implementation strategies, Bioanalytical Services, and compliance requirements specifically tailored for smaller laboratories.

Fundamentals of GLP requirements for small-scale laboratories

GLP is a set of principles developed to ensure data integrity and quality of nonclinical studies that are critical to secure regulatory approval of new pharmaceutical drug products. This quality system covers organizational conditions and processes under which nonclinical studies are performed, planned, recorded, monitored, reported, and archived. GLP labs ensure ethical treatment of animals and help generate evidence of the integrity, reliability, and validity of nonclinical data that regulatory bodies need to approve clinical testing in human subjects.

Good laboratory practices differ from good manufacturing practices. Good manufacturing practices are necessary during the entire drug manufacturing period, while GLP assessment applies to the safety testing period. The US FDA enforces both GLP and GMP.

When is GLP compliance needed?

The following is a comprehensive brief on when laboratories should comply with GLP guidelines.

GLP compliance needed:

• Chemical methods used for characterizing test articles, determining concentration and homogeneity of test articles, and determining the stability of test articles and their mixtures
• Safety studies for identifying potential drug-abuse features of a test article that are necessary for FDA submission as a supplement for marketing or research permit
• Animal safety assessments in target species, udder irritation studies, tissue depletion and residue accumulation studies, and overdosage assessment in target species

GLP compliance is not needed

• Chemical methods implemented to analyze specimens
• Work performed to establish test article specifications or develop chemical procedures for analysis.
• Organoleptic assessment of processed foods
• Safety evaluations of cosmetic products
• Validation studies to confirm the analytical approach implemented to identify the test article concentration in animal tissues
  

Importantly, GLP testing is also not required during early development, such as discovery, concept assessment, basic research, and screening.

Building GLP-compliant infrastructure in small labs

The source of GLP regulations in the US is FDA regulations, specifically 21 CFR 21 58. These regulations are applied during the preapproval phase, where drug developers must demonstrate the safety and effectiveness of a drug candidate in animals before conducting clinical trials. FDA officials can inspect labs, specimens, and records at appropriate times and in a reasonable manner to confirm GLP compliance. In cases where a specific lab refuses to do this inspection, the FDA does not include that study in submission documents for premarket approval. The following are the nine key parameters of GLP regulations for bioanalytical laboratories.

Must Read: Cell-Based Assay in Immunology and Vaccine Research

• Staffing and personnel
  

Minimizing risk and maximizing safety starts with laboratory personnel conducting nonclinical assessments. GLP regulations are hence rules established for lab personnel. There are three primary laboratory roles in nonclinical studies: (a) study analyst, (b) study management, and (c) quality assurance review. While the manager and analyst may be the same individual, quality assurance must be an independent entity.

• Study director
  

The study director should be a scientist or other personnel with appropriate training, experience, and education about the overall responsibility for adequate technical performance.

• QA unit
  

QA processes are critical for minimizing product risks. Hence, regulatory guidance requires laboratories to have a QA unit responsible for complying with GLP regulations.

• Lab facilities
  

Laboratory facilities should be of suitable construction, design, and size. The lab should have adequate facilities for storing articles and animal species, and for test samples and specimens.

• Instrumentation and software
  

GLP regulations ensure that analytical instruments and software are appropriately qualified and optimized. Qualification includes validation assessments to verify the fitness of instruments in producing the intended level of accuracy and reliability.

• Standard operating procedures
  

GLP guidelines have rules for lab operations, including written procedures for conducting nonclinical studies.

• Study protocol
  

Each study should have a written procedure reviewed by the study director. This protocol should include elements such as study purpose, methods, experimental design, product safety, etc.

• Reporting of results
  

Labs must have a dated and signed final report prepared for all studies. This report should include aspects such as data on sponsors, facilities, study director, methods used, study results, etc.

• Records retention
  

The final stage is retaining all documents, data, and specimens and maintaining them for a dedicated period.

Conclusion

Implementing the nine strategies of good laboratory practices in small-scale bioanalytical facilities is vital for robust operational efficiency and regulatory compliance. Besides, systematic planning, quality management, and infrastructure development are critical for establishing successful GLP lab operations. Strategic partnership with bioanalytical service providers can help drug developers complement internal capabilities and accelerate regulatory compliance, while maintaining competitive positioning and optimizing resource utilization. Hence, understanding the role and potential of GLP implementation in small laboratories is essential for competing in regulated marketplaces.